FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma

Phillip H Kuo, Bruce L. McClennan, Kacie Carlson, Lynn D. Wilson, Richard L. Edelson, Peter W. Heald, Michael Girardi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/ computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.

Original languageEnglish (US)
Pages (from-to)74-81
Number of pages8
JournalMolecular Imaging and Biology
Volume10
Issue number2
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Cutaneous T-Cell Lymphoma
Skin
Positron Emission Tomography Computed Tomography
Physical Examination
Lymph Nodes
Biopsy
Glucose

Keywords

  • CutaneousT-cell lymphoma
  • Fluorine-18 fluorodeoxyglucose
  • Mycosis fungoides
  • Positron-emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

Kuo, P. H., McClennan, B. L., Carlson, K., Wilson, L. D., Edelson, R. L., Heald, P. W., & Girardi, M. (2008). FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Molecular Imaging and Biology, 10(2), 74-81. https://doi.org/10.1007/s11307-007-0127-y

FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. / Kuo, Phillip H; McClennan, Bruce L.; Carlson, Kacie; Wilson, Lynn D.; Edelson, Richard L.; Heald, Peter W.; Girardi, Michael.

In: Molecular Imaging and Biology, Vol. 10, No. 2, 03.2008, p. 74-81.

Research output: Contribution to journalArticle

Kuo, PH, McClennan, BL, Carlson, K, Wilson, LD, Edelson, RL, Heald, PW & Girardi, M 2008, 'FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma', Molecular Imaging and Biology, vol. 10, no. 2, pp. 74-81. https://doi.org/10.1007/s11307-007-0127-y
Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Molecular Imaging and Biology. 2008 Mar;10(2):74-81. https://doi.org/10.1007/s11307-007-0127-y
Kuo, Phillip H ; McClennan, Bruce L. ; Carlson, Kacie ; Wilson, Lynn D. ; Edelson, Richard L. ; Heald, Peter W. ; Girardi, Michael. / FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. In: Molecular Imaging and Biology. 2008 ; Vol. 10, No. 2. pp. 74-81.
@article{d345124d5ede4200bd2f604235628866,
title = "FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma",
abstract = "This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/ computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.",
keywords = "CutaneousT-cell lymphoma, Fluorine-18 fluorodeoxyglucose, Mycosis fungoides, Positron-emission tomography",
author = "Kuo, {Phillip H} and McClennan, {Bruce L.} and Kacie Carlson and Wilson, {Lynn D.} and Edelson, {Richard L.} and Heald, {Peter W.} and Michael Girardi",
year = "2008",
month = "3",
doi = "10.1007/s11307-007-0127-y",
language = "English (US)",
volume = "10",
pages = "74--81",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma

AU - Kuo, Phillip H

AU - McClennan, Bruce L.

AU - Carlson, Kacie

AU - Wilson, Lynn D.

AU - Edelson, Richard L.

AU - Heald, Peter W.

AU - Girardi, Michael

PY - 2008/3

Y1 - 2008/3

N2 - This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/ computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.

AB - This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/ computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.

KW - CutaneousT-cell lymphoma

KW - Fluorine-18 fluorodeoxyglucose

KW - Mycosis fungoides

KW - Positron-emission tomography

UR - http://www.scopus.com/inward/record.url?scp=39549105167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549105167&partnerID=8YFLogxK

U2 - 10.1007/s11307-007-0127-y

DO - 10.1007/s11307-007-0127-y

M3 - Article

VL - 10

SP - 74

EP - 81

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 2

ER -